AzTrials
AzTrials

HIV InfectionCODEXNCT01520844

the ANRS CO21 " Extreme " Cohort (CODEX)

A study testing blood sampling in people with HIV Infection, run by ANRS, Emerging Infectious Diseases at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

A consortium of research teams has studied the immunovirological characteristics of these patients: The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
HIV Infection
What is being tested?
blood sampling
Could I receive a placebo?
No, everyone receives an active treatment
How many people
450 participants
Where
1 siteFrance
Study dates
Feb 2012to Sep 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient infected with HIV-1 and not co-infected with HIV-2
  • Age ≥ 18 at enrollment
  • Able to give written consent
  • Covered by French Social Security
  • accept the constraints imposed by the study
  • without antiretroviral therapy for ALT, HIC and ALT HIC groups and a control of viral load after antiretroviral treatment interruption in PTC group
Show all 10Show fewer
  • ALT group: Documented HIV-1 seropositive for at least 8 years with a CD4 count above 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years regardless of the viral load in the absence of antiretroviral treatment
  • HIC group: HIV-1 Seropositivity known for at least five years, asymptomatic, with the last 5 viral loads in HIV-RNA consecutive <400 copies / mL regardless of CD4 count in the absence of antiretroviral treatment
  • ALT HIC group: HIV-1 seropositive known for at least 8 years and CD4 cell counts greater than 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years and with the last 5 viral loads in HIV-RNA consecutive <400 copies / mL in the absence of antiretroviral therapy.
  • PTC group: Patients with plasma HIV RNA > 2000 copies/mL before initiation of antiretroviral therapy. Treatment started during the primary infection (as defined by symptoms associated with seroconversion, as confirmed by a first negative ELISA and/or an incomplete P24-positive Western blot) or during the chronic phase of infection, and maintained for at least 12 months in both cases. Control of viral load after antiretroviral treatment interruption: patients must have at least two available viral load assays after stopping antiretroviral therapy. All viral loads must be <400 copies/mL for 12 months or more after stopping antiretroviral therapy, with the possible exception of one blip (one viral load above 400 copies/mL between two viral loads <400 copies/mL at least one month apart from the blip; in this case at least three viral load assays will be required). The last plasma viral load value at the time of inclusion must always be <400 copies/mL

Who cannot join

  • Under protection(saving) of justice

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Olivier Lambotte, Professor contact

01 49 59 67 54

olivier.lambotte@bct.aphp.fr

France1 site, 1 recruiting
  • Lambotte

    Le Kremlin-Bicêtre

    Recruiting

Other trials in France

About this study

Official title: Multicentric Cohort of HIV Patient With Extrem Profil

A consortium of research teams has studied the immunovirological characteristics of these patients:

The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study

Read the detailed description

Two cohorts of patients with a phenotype of HIV resistance exist in France. The ANRS CO15 ALT cohort was set up in 1994. 71 patients were enrolled defined on immunological criteria: CD4 T cell count above 600/mm3 with a stable or increasing count (positive or zero slopes) on at least three consecutive exams performed during the last 5 years whatever the viral load was, with a known HIV infection for at least 8 years. A consortium of research teams has studied the immunovirological characteristics of these patients. After 16 years of follow-up, 6 patients are still actively followed. The main results have shown the lack of deletion in viral genes nor any functional viral defects, a small size for the viral reservoir, and distinctive genetic characteristics of the host (HLA, chemokines) which lead to potent immune cell responses associated with virus control.

The ANRS CO18 HIV Controller cohort set up in 2009 is stemming from the French National Observatory of HIV Controllers which was active between 2006 and 2008 (Study ANRS EP36). 152 patients are enrolled who are defined on virological criteria: the last 5 plasmatic viral loads should be below 400 copies/mL without any antiretroviral treatment, in HIV-infected patients for more than 5 years. A consortium of research teams has studied these patients and has shown that Controllers are infected with replication-competent HIV, that HIV infects CD4 T cells but that the viral replication in CD4 T cells is fully controlled by CD8 T cells.

In addition, the ANRS EP47 VISCONTI study identified 14 patients who had been able to maintain plasmatic viral loads below 400 copies/ml for more than 7 years in the absence of antiretroviral treatment. Differently from HIV controllers, naïve of antiretroviral treatment, the patients from the VISCONTI study started therapy within ten weeks of primary infection and kept it for a median of three years before treatment discontinuation (Post-Treatment Controllers or PTC). The initial analyses revealed important clinical and immunogenetic differences between post-treatment and natural controllers, suggesting that PTC were not naturally predispose to control infection and that they succeeded thanks to initial therapeutic intervention. The mechanisms associated with long-term control in post-treatment controllers also appear different from the main mechanisms identified in HIV controllers. The main objective now is to gather in a common cohort patients with a particular resistance to HIV infection, either with an immunological control (ALT) or a natural (HIV Controllers) or induced virological control (PTC). The enrolled patients will be the patients already enrolled in the cohorts CO15 and CO18, the ANRSEP47 VISCONTI study, and new patients. This will allow common physiopathological studies to precise the mechanisms leading to the virus control and CD4 homeostasy. A better knowledge of the mechanisms of viral control and immune response preservation is very important in the setting of vaccine perspectives and in the perspective of implementing new therapeutic interventions to induce remission of HIV infection. This cohort will allow common research projects with common funding, a better visibility both for clinicians who see patients with unusual phenotypes and for international research. Such a cohort will be unique in the world by its size and the presence of these three complementary groups of patients. The two main objectives for the " Extreme " cohort (ANRS CO21 CODEX) are clinical and immunovirological. We wish to precise the impact of a prolonged untreated HIV infection, to describe the frequency of the "immunological escapes" (CD4 T cell decrease) or "virological escapes" (permanent or transient viral load increase), and to identify predictive markers of HIV control. We wish to study the genetic characteristics of the patients and those of their viruses, the innate and adaptative immune responses directed against HIV and other viruses, the consequences of inflammation, and the characteristics of the loss of control.

Conditions
HIV Infection
Being tested
blood sampling
Medical subject headings
HIV Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01520844
Study groupRoleWhat they receive
Cohort studyOtherBlood sampling
Receives: Biological: blood sampling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. clinical and immuno-virological

    Measured: up to 5 years

Secondary outcomes (4)
  1. mechanisms leading to the virus control and CD4 homeostasy with physiopathological studies

    Measured: up to 5 years

  2. impact of a prolonged untreated HIV infection,

    Measured: up to 5 years

  3. frequency of the "immunological escapes" (CD4 T cell decrease) or "virological escapes" (permanent or transient viral load increase)

    Measured: up to 5 years

  4. genetic characteristics of the patients and those of their viruses, the innate and adaptative immune responses directed against HIV and other viruses, the consequences of inflammation, and the characteristics of the loss of control

    Measured: up to 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jan 2012 (estimated)
  2. Study startFeb 2012
  3. Primary completionSep 2029 (estimated)
  4. Study completionSep 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
450 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01520844
Sponsor's protocol ID
ANRS CO21 CODEX
Acronym
CODEX
Status last verified
Apr 2026
First submitted
9 Aug 2011
Last updated
7 Apr 2026
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing blood sampling in people with HIV Infection, run by ANRS, Emerging Infectious Diseases at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Olivier Lambotte, Professor (01 49 59 67 54, olivier.lambotte@bct.aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

clinical and immuno-virological (time frame: up to 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in